Ebola Virus Infection Associated with Transmission from Survivors.


Journal

Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155

Informations de publication

Date de publication:
02 2019
Historique:
pubmed: 1 12 2018
medline: 30 7 2019
entrez: 1 12 2018
Statut: ppublish

Résumé

Ebola virus (EBOV) can persist in immunologically protected body sites in survivors of Ebola virus disease, creating the potential to initiate new chains of transmission. From the outbreak in West Africa during 2014-2016, we identified 13 possible events of viral persistence-derived transmission of EBOV (VPDTe) and applied predefined criteria to classify transmission events based on the strength of evidence for VPDTe and source and route of transmission. For 8 events, a recipient case was identified; possible source cases were identified for 5 of these 8. For 5 events, a recipient case or chain of transmission could not be confidently determined. Five events met our criteria for sexual transmission (male-to-female). One VPDTe event led to at least 4 generations of cases; transmission was limited after the other events. VPDTe has increased the importance of Ebola survivor services and sustained surveillance and response capacity in regions with previously widespread transmission.

Identifiants

pubmed: 30500321
doi: 10.3201/eid2502.181011
pmc: PMC6346469
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Pagination

249-255

Références

Open Forum Infect Dis. 2017 Jul 22;4(3):ofx155
pubmed: 29670927
J Clin Diagn Res. 2015 Oct;9(10):LA01-2
pubmed: 26557543
MMWR Morb Mortal Wkly Rep. 2016 Jul 08;65(26):681-2
pubmed: 27388584
J Infect Dis. 1999 Feb;179 Suppl 1:S28-35
pubmed: 9988162
Clin Infect Dis. 2017 Feb 15;64(4):513-516
pubmed: 27940938
N Engl J Med. 2017 Oct 12;377(15):1428-1437
pubmed: 26465681
BMJ Open. 2016 Jan 07;6(1):e008859
pubmed: 26743699
Lancet Infect Dis. 2015 Aug;15(8):905-12
pubmed: 25910637
Klin Wochenschr. 1968 Apr 1;46(7):398-400
pubmed: 4971902
N Engl J Med. 2015 Dec 17;373(25):2448-54
pubmed: 26465384
Virus Evol. 2016 Jun 22;2(1):vew016
pubmed: 28694998
Clin Infect Dis. 2016 Nov 15;63(10):1353-1356
pubmed: 27585800
Glob Health Action. 2014 Nov 07;7:26058
pubmed: 25382685
Bull World Health Organ. 1978;56(2):247-70
pubmed: 307455
N Engl J Med. 2015 Jun 18;372(25):2423-7
pubmed: 25950269
Sci Adv. 2016 Apr 29;2(4):e1600378
pubmed: 27386513
J Infect Dis. 1999 Feb;179 Suppl 1:S170-6
pubmed: 9988181
Euro Surveill. 2015;20(48):30083
pubmed: 26676163
Lancet Infect Dis. 2015 May;15(5):507-8
pubmed: 25932579
Nature. 2015 Mar 5;519(7541):13-4
pubmed: 25739606
J Infect Dis. 2007 Nov 15;196 Suppl 2:S142-7
pubmed: 17940942
Emerg Infect Dis. 2016 Dec;22(12):2149-2152
pubmed: 27869596
N Engl J Med. 2017 Oct 12;377(15):1480-1482
pubmed: 26465064
Lancet Infect Dis. 2018 Sep;18(9):1015-1024
pubmed: 30049622
MMWR Morb Mortal Wkly Rep. 2015 May 8;64(17):479-81
pubmed: 25950255

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH